An “Age” Structured Model of Hematopoietic Stem Cell Organization with Application to Chronic Myeloid Leukemia

Previously, we have modeled hematopoietic stem cell organization by a stochastic, single cell-based approach. Applications to different experimental systems demonstrated that this model consistently explains a broad variety of in vivo and in vitro data. A major advantage of the agent-based model (ABM) is the representation of heterogeneity within the hematopoietic stem cell population. However, this advantage comes at the price of time-consuming simulations if the systems become large. One example in this respect is the modeling of disease and treatment dynamics in patients with chronic myeloid leukemia (CML), where the realistic number of individual cells to be considered exceeds 106. To overcome this deficiency, without losing the representation of the inherent heterogeneity of the stem cell population, we here propose to approximate the ABM by a system of partial differential equations (PDEs). The major benefit of such an approach is its independence from the size of the system. Although this mean field approach includes a number of simplifying assumptions compared to the ABM, it retains the key structure of the model including the “age” structure of stem cells. We show that the PDE model qualitatively and quantitatively reproduces the results of the agent-based approach.

[1]  O. Diekmann,et al.  The Dynamics of Physiologically Structured Populations , 1986 .

[2]  Kendall E. Atkinson An introduction to numerical analysis , 1978 .

[3]  S. Forman,et al.  Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. , 2007, Cancer research.

[4]  Doron Levy,et al.  A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia , 2008, Bulletin of mathematical biology.

[5]  N. Cross,et al.  Detection and quantification of residual disease in chronic myelogenous leukemia , 2000, Leukemia.

[6]  M. Loeffler,et al.  Stem Cell Fate Analysis Revisited: Interpretation of Individual Clone Dynamics in the Light of a New Paradigm of Stem Cell Organization , 2007, Journal of biomedicine & biotechnology.

[7]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[8]  Ingo Roeder,et al.  A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. , 2002, Experimental hematology.

[9]  Branford,et al.  Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics , 1999, British journal of haematology.

[10]  C. Eaves,et al.  Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate , 2006, Clinical Cancer Research.

[11]  Ingo Roeder,et al.  Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.

[12]  Ingo Roeder,et al.  Competitive clonal hematopoiesis in mouse chimeras explained by a stochastic model of stem cell organization. , 2005, Blood.

[13]  Ajoy Ghatak,et al.  The Dirac Delta Function , 2004 .

[14]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[15]  Ingo Roeder,et al.  Tissue Stem Cells: Definition, Plasticity, Heterogeneity, Self-Organization and Models – A Conceptual Approach , 2002, Cells Tissues Organs.

[16]  Franziska Michor,et al.  Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.

[17]  I. Glauche,et al.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.

[18]  K. B. Oldham,et al.  An Atlas of Functions. , 1988 .

[19]  Michael Cross,et al.  Lineage Specification of Hematopoietic Stem Cells: Mathematical Modeling and Biological Implications , 2007, Stem cells.

[20]  Doron Levy,et al.  Modeling Imatinib-Treated Chronic Myelogenous Leukemia: Reducing the Complexity of Agent-Based Models , 2008, Bulletin of mathematical biology.

[21]  R. LeVeque Numerical methods for conservation laws , 1990 .

[22]  Michael C Mackey,et al.  A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.

[23]  Begnaud Francis Hildebrand,et al.  Introduction to numerical analysis: 2nd edition , 1987 .

[24]  M. Loeffler,et al.  Mathematical Modeling of Genesis and Treatment of Chronic Myeloid Leukemia , 2008, Cells Tissues Organs.

[25]  Ingo Roeder,et al.  Asymmetry of stem cell fate and the potential impact of the niche , 2006, Stem Cell Reviews.

[26]  Michael Luck,et al.  Understanding agent systems, Second Edition , 2004, Springer series on agent technology.

[27]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[28]  Michael Luck,et al.  Understanding Agent Systems , 2001, Springer Series on Agent Technology.

[29]  P. Vigneri,et al.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.

[30]  F. Michor,et al.  Reply: The long-term response to imatinib treatment of CML , 2007, British Journal of Cancer.

[31]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.